脑脊液中托米纳森度与亨廷顿病患者生物标志物变化之间的定量关系
Yumi Yamamoto1, Hanna E Silber Baumann1, Marcus Björnsson2
1Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
British journal of clinical pharmacology
|November 25, 2025
概括
托米纳森降低了在亨廷顿病中突变的亨廷丁蛋白 (mHTT).
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 遗传学 是一个遗传学.
背景情况:
- 亨廷顿病 (HD) 是一种进展性神经退行性疾病,由亨廷丁基因突变引起.
- 突变亨廷丁 (mHTT) 蛋白质积累是HD病变发生的关键驱动因素.
- 目前的治疗方法主要是治疗症状;正在研究疾病修饰疗法.
研究的目的:
- 描述托米纳森暴露和脑脊液 (CSF) 中的mHTT减少之间的药理动力学和药理动力学 (PKPD) 关系.
- 调查托米纳森对其他CSF生物标志物的影响.
- 为未来的临床试验提供最佳剂量策略的信息.
主要方法:
- 非线性混合效应群体PKPD建模应用于四项临床研究中的915名参与者的数据.
- 数据包括每4周,8周或16周内注射的多种多明森剂量 (30-120毫克).
- 进行了暴露-反应 (ER) 分析和PK/PD模拟.
主要成果:
- 一个PKPD模型证实了tominersen度与mHTT减少之间的关系,IC50为4.18 ng/mL.
- 较高的托米纳森暴露与较大的mHTT减少相关 (54%),但也导致神经损伤和炎症生物标志物的短暂增加.
- 较低的托米纳森暴露显示了较少的mHTT减少 (24%) 但更有利的生物标志物概况.
结论:
- 该PKPD模型量化验证了tominersen对降低CSFmHTT水平的剂量依赖作用.
- 较低的托米纳森暴露水平可能为亨廷顿病治疗提供更有利的益处风险平衡.
- 这些发现支持对正在进行的和未来的临床研究进行精细的剂量选择.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
09:06Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
12.5K
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...